TIL Q4 2023 Earnings — Instil Bio, Inc. Revenue & Financial Results | Market Cap Arena

TILInstil Bio, Inc.

$62M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$1M

Operating Income

-$13M

Net Income

-$13M

EPS (Diluted)

$-1.99

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$13M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$326M

Total Liabilities

$100M

Stockholders' Equity

$226M

Cash & Equivalents

$9M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$1M	$0	—
Operating Income	-$13M	-$57M	+77.4%
Net Income	-$13M	-$54M	+76.0%